Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals Inc. (LXRX) delivers innovative genomic-driven therapies for chronic diseases through its proprietary drug discovery platform. This page provides centralized access to official press releases, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and industry observers will find timely updates on key initiatives including neuropathic pain treatment LX9211, diabetes therapies, and cardiovascular research. The resource aggregates regulatory milestones, partnership announcements, and scientific presentations while maintaining strict compliance with financial disclosure standards.
All content undergoes verification against primary sources to ensure accuracy. Users can monitor developments across Lexicon's pipeline – from preclinical research to commercialized products like INPEFA® – through curated news streams free of promotional language.
Bookmark this page for efficient tracking of LXRX's progress in advancing non-opioid pain management solutions and targeted metabolic therapies. Regular updates provide critical insights into the company's position within the evolving biopharmaceutical landscape.
Lexicon Pharmaceuticals announced significant findings from the SCORED Phase 3 clinical trial for sotagliflozin, presented at the American College of Cardiology’s 71st Annual Scientific Session. The analysis, involving 10,584 patients with type 2 diabetes and chronic kidney disease, revealed a 21% reduction in major adverse cardiovascular events (MACE) in patients with cardiovascular disease and a 26% reduction in those without. The results underscore sotagliflozin's potential in reducing cardiovascular death, myocardial infarction, and stroke, reinforcing its therapeutic significance.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a late-breaking presentation at the American College of Cardiology’s 71st Annual Scientific Session. Dr. Deepak L. Bhatt will present a secondary analysis of sotagliflozin data from the SCORED Phase 3 trial on April 2, 2022. The analysis will focus on the reduction of cardiovascular death, myocardial infarction, and stroke. Sotagliflozin is approved in the EU for type 1 diabetes. Despite its approval, commercial launch in the U.S. is pending. For more details, visit Lexicon's website.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has secured a loan facility with Oxford Finance LLC, offering up to $150 million to fund commercial preparations and the potential launch of sotagliflozin for heart failure. The agreement includes four tranches, with an initial $25 million funded at closing. Additional funds are contingent upon regulatory approval from the FDA. The loan carries a floating interest rate starting at 8.01%. Lexicon also granted warrants for 420,673 shares to Oxford, exercisable through 2027, providing a financial flexibility as the company approaches important regulatory milestones.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its financial results for Q4 and full-year 2021, reporting negligible revenues due to the sale of its XERMELO product in 2020. R&D expenses surged to $16.5 million in Q4 2021, reflecting increased costs for LX9211 studies, while SG&A expenses rose to $8.8 million. The company's net loss for Q4 was $25.6 million, compared to $5.5 million in Q4 2020, totaling a net loss of $87.8 million for 2021. Lexicon also voluntarily withdrew its NDA for sotagliflozin to correct a technical issue, with plans to resubmit in Q2 2022.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the voluntary withdrawal of its New Drug Application (NDA) for sotagliflozin due to a recently identified technical issue. The company plans to resubmit the NDA after correcting the submission in consultation with the FDA. The resubmission is prioritized and expected early in Q2 2022. Sotagliflozin is already approved in the EU for type 1 diabetes but is not yet commercially launched in the U.S.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its Q4 2021 financial results on February 28, 2022, prior to market opening. A conference call and webcast will follow at 8:00 a.m. ET to discuss financial outcomes and business updates. Lexicon focuses on pioneering medicines through its Genome5000™ program, which studies gene roles and targets for therapeutic potential across various diseases, including heart failure and diabetes. The company has advanced one medicine to market and has multiple candidates in development.
Lexicon Pharmaceuticals (LXRX) has submitted a New Drug Application (NDA) for sotagliflozin to the FDA, targeting heart failure in patients with type 2 diabetes. If approved, the launch is anticipated in the second half of 2022. The proposed label highlights recent heart failure concerns as per the SOLOIST-WHF study. Additionally, Lexicon expects results from two Phase 2 studies on LX9211 for neuropathic pain in early 2022. Both initiatives address significant market needs, with the potential for blockbuster success.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that CEO Lonnel Coats will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 a.m. ET. The presentation will be accessible via a live webcast on the company's website, with an archived version available for two weeks post-event. Lexicon is focused on developing innovative medicines, leveraging its Genome5000™ program to identify therapeutic protein targets across various diseases, including neuropathic pain and diabetes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has submitted a New Drug Application (NDA) to the FDA for sotagliflozin, aimed at reducing the risk of cardiovascular death and hospitalization in adults with type 2 diabetes and heart failure. Supported by findings from the Phase 3 SOLOIST and SCORED studies, the NDA submission marks a significant step towards potential market approval. Both clinical trials achieved their primary endpoints, indicating that sotagliflozin could offer essential benefits to patients suffering from these conditions.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its virtual participation in two upcoming healthcare conferences. The Jefferies London Healthcare Conference will occur from November 16-19, 2021, with CEO Lonnel Coats presenting on-demand starting November 18 at 3:00 am ET. The Piper Sandler 33rd Annual Healthcare Conference will take place from November 30 to December 2, 2021, featuring a fireside chat with executive management available on-demand starting November 22 at 10:00 am ET. Recordings will be accessible on Lexicon's website for two weeks post-event.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
